Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 542-544, 2006.
Article
in Chinese
| WPRIM
| ID: wpr-236937
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effectiveness and safety of domestically produced recombinant human interleukin 11 (rhIL-11) for the treatment of chemotherapy- induced thrombocytopenia.</p><p><b>METHODS</b>A total of 32 solid cancer patients who developed chemotherapy-induced thrombocytopenia ( _70 x 10(9)/L) after the first cycle of chemotherapy was studied by self-cross control. The patients were given subcutaneous injection of rhIL-11 (25 microg x kg(-1) x d(-1)) for 7 to 14 consecutive days or until platelet count > or = 100 x 10(9)/L during the second cycle of chemotherapy using the identical regimen as in the first cycle.</p><p><b>RESULTS</b>The mean platelet count of the patients after rhIL-11 treatment was higher at different time points during the second cycle of chemotherapy than that during the first cycle of chemotherapy with the mean platelet count of (110.2 +/- 53.5) x 10(9)/L in the first cycle of chemotherapy versus (55.6 +/- 46.8) x 10(9)/L in the second cycle of chemotherapy (P < 0. 01). Patients with platelet count < or = 50 x 10(9)/L was 4/32 (12.5%) in the first cycle of chemotherapy and 12/32 (37.5%) in the second cycle of chemotherapy (P < 0.01). The time recovery to the normal platelet count was 2 - 18 days (median 5 days) in the first cycle of chemotherapy versus 5 - 27 days (median 12 days) in the second cycle of chemotherapy (P < 0.01). The case/frequency of the platelet transfusion was 2/2 in the first cycle of chemotherapy, while it was 7/9 in the second cycle of chemotherapy (P < 0.01). The major adverse reactions relative to rhIL-11 treatment were fatigue, myalgia/arthralgia, ache, headache, palpitation, edema and fever, most of which could be relieved automatically without any specific treament. However, some 3 grade side effects such as fatigue, myalgia/arthralgia and headache needed proper medication.</p><p><b>CONCLUSION</b>rhIL-11 is safe and effective for chemotherapy-induced thrombocytopenia with mild and manageable side effects.</p>
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Platelet Count
/
Stomach Neoplasms
/
Thrombocytopenia
/
Recombinant Proteins
/
Breast Neoplasms
/
Antineoplastic Combined Chemotherapy Protocols
/
Carboplatin
/
Treatment Outcome
/
Paclitaxel
/
Interleukin-11
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
Chinese
Journal:
Chinese Journal of Oncology
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS